Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Normast MPS
- Development stage
- Unknown
- Lead developer
- Epitech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Normast MPS is a food for special medical purposes (FSMP) developed and marketed by Epitech Group SpA. It contains a patented combination of micronized palmitoylethanolamide (PEA-m, 300 mg) and ultra-micronized palmitoylethanolamide (PEA-um, 600 mg). As an ALIAmide (Autacoid Local Injury Antagonist amide), its mechanism of action involves the modulation of non-neuronal immune cells, including mast cells, microglia, and astrocytes, to control neuroinflammation and pain sensitization. The product is specifically indicated for the management of Mixed Pain Syndrome (MPS), particularly neuropathic and mixed pain associated with osteo-articular conditions such as Complex Regional Pain Syndrome and Patellofemoral Pain, as well as broader neurodegenerative and neuroinflammatory conditions. It is administered orally and is commercially available in Italy.
- Brand names
- Normast MPSNORMAST MPS 20 COMPRESSE
- Other names
- palmitoylethanolamide micronized and ultra-micronizedPEA-m + PEA-um
02
Targets
GPR119 (Glucose-dependent insulinotropic receptor)GPR55 (G protein-coupled receptor 55)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on Normast MPS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Normast MPS.